Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
7.40
-0.29 (-3.77%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
7.40
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
BridgeBio Oncology Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda renin-angiotensin tizimi va fosfoinozitid-3-kinaza xavfli o'smalarini davolash uchun kichik molekulali terapevtik vositalarni ishlab chiqish bilan shug'ullanadi. Kompaniya KRASG12C mutatsiyali mayda hujayrali o'pka saratoni bilan og'rigan bemorlarni davolash uchun I bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekulali to'g'ridan-to'g'ri ingibitor BBO-8520ni ishlab chiqadi; va KRAS G12D va KRAS G12V hujayrali ksenograft modellariga ega bemorlarni davolash uchun I bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekulali pan-KRAS ingibitor BBO-11818ni ishlab chiqadi. U, shuningdek, HER2-musbat ko'krak bezi saratoni, HR-musbat/HER2-manfiy ko'krak bezi saratoni, KRAS mutatsiyali kolorektal saraton va KRAS mutatsiyali mayda hujayrali o'pka saratoni bilan og'rigan bemorlarni davolash uchun I bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekulali BBO-10203ni ishlab chiqishda ishtirok etadi; va o'smalari bo'lgan bemorlar uchun aniq onkologik vositalarni ishlab chiqadi. Kompaniya 2016 yilda tashkil etilgan bo'lib, shtab-kvartirasi Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Non-Executive Director & Chair of the Advisory Board |
| Dr. Neil Kumar Ph.D. | Executive Chairman |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical & Development Officer |
| Mr. Aaron Chan J.D. | Vice President of Legal |
| Mr. Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Mr. Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls |
| Mr. Idan Elmelech M.A., M.B.A. | Chief Operating Officer |
| Mr. Marc Cobo | VP of Finance & Controller |
| Mr. Rui Xu Ph.D. | Senior Vice President of Drug Discovery |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 8-K | bbot-20260512.htm |
| 2026-05-12 | 10-Q | bbot-20260331.htm |
| 2026-04-30 | POS AM | d480864dposam.htm |
| 2026-04-28 | DEFA14A | d95309ddefa14a.htm |
| 2026-04-28 | DEF 14A | d133143ddef14a.htm |
| 2026-04-28 | ARS | d134712dars.pdf |
| 2026-04-23 | 8-K | d253464d8k.htm |
| 2026-03-26 | 8-K | d126641d8k.htm |
| 2026-03-05 | 8-K | bbot-20260305.htm |
| 2026-03-05 | 10-K | bbot-20251231.htm |